Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H19N2O2.CH3O4S |
| Molecular Weight | 334.389 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COS([O-])(=O)=O.CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C
InChI
InChIKey=OSZNNLWOYWAHSS-UHFFFAOYSA-M
InChI=1S/C12H19N2O2.CH4O4S/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5;1-5-6(2,3)4/h6-9H,1-5H3;1H3,(H,2,3,4)/q+1;/p-1
DescriptionSources: http://www.drugbank.ca/drugs/DB01400Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/neostigmine-methylsulfate-injection.html
Sources: http://www.drugbank.ca/drugs/DB01400
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/neostigmine-methylsulfate-injection.html
Neostigmine is a cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. By inhibiting acetylcholinesterase, more acetylcholine is available in the synapse, therefore, more of it can bind to the fewer receptors present in myasthenia gravis and can better trigger muscular contraction. Neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone.
CNS Activity
Sources: http://www.drugbank.ca/drugs/DB01400
Curator's Comment: Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
300 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/382915/ |
0.07 mg/kg single, intravenous dose: 0.07 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
NEOSTIGMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
69.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/382915/ |
0.07 mg/kg single, intravenous dose: 0.07 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
NEOSTIGMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
79.8 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/382915/ |
0.07 mg/kg single, intravenous dose: 0.07 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
NEOSTIGMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.5 h |
0.03 mg/kg single, intravenous dose: 0.03 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
NEOSTIGMINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
75% |
0.03 mg/kg single, intravenous dose: 0.03 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
NEOSTIGMINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes | yes (co-administration study) Comment: information obtained from abstract: AUC of coadministered drug, parathion, parathion was significantly greater than control (65.1 versus 74.3 microg min/ml) |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Prolonged curarization in a patient with renal failure. Case report. | 1971 May |
|
| Thioridazine toxicity. Agranulocytosis and hepatitis with encephalopathy. | 1973 Apr 23 |
|
| Myasthenia syndrome during penicillamine treatment. | 1975 Jun 28 |
|
| Effect of halogenated anaesthetics on heart rate changes during reversal of neuromuscular block with glycopyrrolate and neostigmine. | 1984 Nov |
|
| Abnormal responses to morphine-neostigmine in patients with undefined biliary type pain. | 1985 Dec |
|
| Refractory bradycardia after reversal of muscle relaxant in a diabetic with vagal neuropathy. | 1986 Nov |
|
| Spinal cholinergic neurons and the expression of morphine withdrawal symptoms in the rat. | 1987 Mar |
|
| Portal hypertension secondary to azathioprine in myasthenia gravis. | 1988 Dec |
|
| Effects of adrenergic blockers on central nervous system-mediated hyperglycemia in fed rats. | 1992 May |
|
| Interaction between intrathecal neostigmine and epidural clonidine in human volunteers. | 1996 Aug |
|
| Subarachnoid neostigmine does not affect blood pressure or heart rate during bupivacaine spinal anesthesia. | 1996 Nov-Dec |
|
| Postoperative reparalysis after rocuronium following nebulized epinephrine. | 1997 Mar |
|
| Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine-morphine administration. | 1997 Nov |
|
| International Association for the Study of Pain--Ninth World congress. 22-27 August 1999, Vienna, Austria. | 1999 Nov |
|
| Low-dose clonidine and neostigmine prolong the duration of intrathecal bupivacaine-fentanyl for labor analgesia. | 2000 Feb |
|
| The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure-prone and withdrawal seizure-resistant selected mouse lines. | 2002 Aug |
|
| Factors affecting gallbladder motility: drugs. | 2003 Jul |
|
| Probiotics and functional abdominal bloating. | 2004 Jul |
|
| Masseter muscle spasm following atracurium. | 2004 May |
|
| Phosphorus-doped and undoped glassy carbon indicator electrodes in controlled-current potentiometric titrations of bromide- or chloride-containing active ingredients in some pharmaceutical preparations. | 2005 Feb 23 |
|
| Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. | 2005 Jul 12 |
|
| The contribution of Dr. Mary Walker towards myasthenia gravis and periodic paralysis whilst working in poor law hospitals in London. | 2005 Jun |
|
| Ocular myasthenia gravis and auto-immune thyroiditis in children. | 2005 Nov |
|
| Heart block and prolonged Q-Tc interval following muscle relaxant reversal: a case report. | 2008 Feb |
|
| Sphincter of Oddi and its dysfunction. | 2008 Jan |
|
| Neostigmine and pilocarpine attenuated tumour necrosis factor alpha expression and cardiac hypertrophy in the heart with pressure overload. | 2008 Jan |
|
| Neostigmine decreases bupivacaine use by patient-controlled epidural analgesia during labor: a randomized controlled study. | 2009 Aug |
|
| Relationship between anti-acetylcholine receptor antibody titres and severity of myasthenia gravis. | 2009 May |
|
| Dr Lazar Remen (1907-74): a forgotten pioneer in the treatment of myasthenia gravis. | 2009 May |
|
| Myasthenia gravis and autoimmune Addison disease in a patient with thymoma. | 2009 Sep |
|
| The validation of an in vitro colonic motility assay as a biomarker for gastrointestinal adverse drug reactions. | 2010 Jun 15 |
|
| A comparative study of two different doses of epidural neostigmine coadministered with lignocaine for post operative analgesia and sedation. | 2010 Oct |
Patents
Sample Use Guides
The recommended dose range of Neostigmine Methylsulfate Injection is 0.03 mg/kg to 0.07 mg/kg administered as an intravenous bolus.
Route of Administration:
Intravenous
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 522.1503
Created by
admin on Fri Dec 15 16:14:47 GMT 2023 , Edited by admin on Fri Dec 15 16:14:47 GMT 2023
|
||
|
FDA ORPHAN DRUG |
359611
Created by
admin on Fri Dec 15 16:14:47 GMT 2023 , Edited by admin on Fri Dec 15 16:14:47 GMT 2023
|
||
|
NCI_THESAURUS |
C47792
Created by
admin on Fri Dec 15 16:14:47 GMT 2023 , Edited by admin on Fri Dec 15 16:14:47 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
98IMH7M386
Created by
admin on Fri Dec 15 16:14:47 GMT 2023 , Edited by admin on Fri Dec 15 16:14:47 GMT 2023
|
PRIMARY | |||
|
C76613
Created by
admin on Fri Dec 15 16:14:47 GMT 2023 , Edited by admin on Fri Dec 15 16:14:47 GMT 2023
|
PRIMARY | |||
|
98IMH7M386
Created by
admin on Fri Dec 15 16:14:47 GMT 2023 , Edited by admin on Fri Dec 15 16:14:47 GMT 2023
|
PRIMARY | |||
|
1460000
Created by
admin on Fri Dec 15 16:14:47 GMT 2023 , Edited by admin on Fri Dec 15 16:14:47 GMT 2023
|
PRIMARY | |||
|
51-60-5
Created by
admin on Fri Dec 15 16:14:47 GMT 2023 , Edited by admin on Fri Dec 15 16:14:47 GMT 2023
|
PRIMARY | |||
|
200-109-5
Created by
admin on Fri Dec 15 16:14:47 GMT 2023 , Edited by admin on Fri Dec 15 16:14:47 GMT 2023
|
PRIMARY | |||
|
100000086473
Created by
admin on Fri Dec 15 16:14:47 GMT 2023 , Edited by admin on Fri Dec 15 16:14:47 GMT 2023
|
PRIMARY | |||
|
SUB20700
Created by
admin on Fri Dec 15 16:14:47 GMT 2023 , Edited by admin on Fri Dec 15 16:14:47 GMT 2023
|
PRIMARY | |||
|
DBSALT000128
Created by
admin on Fri Dec 15 16:14:47 GMT 2023 , Edited by admin on Fri Dec 15 16:14:47 GMT 2023
|
PRIMARY | |||
|
m7819
Created by
admin on Fri Dec 15 16:14:47 GMT 2023 , Edited by admin on Fri Dec 15 16:14:47 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL278020
Created by
admin on Fri Dec 15 16:14:47 GMT 2023 , Edited by admin on Fri Dec 15 16:14:47 GMT 2023
|
PRIMARY | |||
|
NEOSTIGMINE METHYLSULFATE
Created by
admin on Fri Dec 15 16:14:47 GMT 2023 , Edited by admin on Fri Dec 15 16:14:47 GMT 2023
|
PRIMARY | Description: A white, crystalline powder; odourless. Solubility: Very soluble in water; freely soluble in ethanol (~750 g/l) TS. Category: Cholinergic. Storage: Neostigmine metilsulfate should be kept in a tightly closed container, protected from light. Definition: Neostigmine metilsulfate contains not less than 98.0% and not more than 100.5% of C13H22N2O6S, calculated with reference to the dried substance. | ||
|
93753
Created by
admin on Fri Dec 15 16:14:47 GMT 2023 , Edited by admin on Fri Dec 15 16:14:47 GMT 2023
|
PRIMARY | |||
|
7316
Created by
admin on Fri Dec 15 16:14:47 GMT 2023 , Edited by admin on Fri Dec 15 16:14:47 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID40199003
Created by
admin on Fri Dec 15 16:14:47 GMT 2023 , Edited by admin on Fri Dec 15 16:14:47 GMT 2023
|
PRIMARY | |||
|
5824
Created by
admin on Fri Dec 15 16:14:47 GMT 2023 , Edited by admin on Fri Dec 15 16:14:47 GMT 2023
|
PRIMARY | |||
|
7514
Created by
admin on Fri Dec 15 16:14:47 GMT 2023 , Edited by admin on Fri Dec 15 16:14:47 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
